Obtenga las últimas noticias sobre las acciones de Ardelyx con actualizaciones sobre las tendencias del mercado, las finanzas y el análisis de Benzinga. Manténgase informado sobre el rendimiento de ARDX

Últimas noticias sobre

ARDELYX INC

Ardelyx

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

San,Jose,,Ca,,Usa,-,Nov,29,,2023:,Twilio,Ads

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AAPL

ADIL

AMZN

ARDX

CNEY

EXAS

GNLN

HCTI

KIDZ

NPKI

PAPL

PLRZ

SOPA

SPHL

TEAM

TREE

TWLO

Las acciones de Twilio subieron más de un 9 % tras publicar sólidos resultados financieros trimestrales. ¿Quién más sorprendió?

Las acciones de Twilio (TWLO) suben más de un 9%; Aquí están 20 acciones que se mueven en el premercado

Ardelyx Inc

ArdCoin

Press Releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims  On Behalf of Investors of Ardelyx, Inc. - ARDX

Legal

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX

Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025

Earnings

Ardelyx Reports Second Quarter 2025 Financial Results and Provides Business Update

Ardelyx Announces Changes to the Executive Leadership Team

Ardelyx to Participate in Upcoming Investor Conferences

Management

Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer

Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025

AnaptysBio

Bicara Therapeutics

CureVac

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Immatics

MiMedx Group

Nanobiotix

Anbio Biotechnology - Class A Ordinary Shares

Anbio Biotechnology

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Oruka Therapeutics

Precigen

Pharming Group N.V. - ADS, each representing 10 ordinary shares

Pharming

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

Prime Medicine

Relay Therapeutics

Sionna Therapeutics

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

ARS Pharmaceuticals

Spyre Therapeutics

Tango Therapeutics

Tourmaline Bio

Upstream Bio

Xencor

Zenas BioPharma

Zymeworks

Piper Sandler

Wedbush

Raymond James

HC Wainwright & Co.

Citigroup

Comments

Ardelyx Noticias bursátiles

Noticias

Últimas noticias sobre

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL